Literature DB >> 21751003

Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan.

Muhammad U Rashid, Sidra Gull, Saima Faisal, Saba Khaliq, Kashif Asghar, Neelam Siddiqui, Asim Amin, Ute Hamann.   

Abstract

Pathogenic germ line mutations in the BRCA1 and BRCA2 genes confer elevated risk of breast and ovarian cancer in females and have a link with variety of cancers other than breast cancer in males. Here we report the first case of a 45-year-old Pakistani male with renal cell carcinoma who was identified to harbor a disease-associated BRCA1 germ line mutation, 2080insA. Detailed description of the family history, clinical presentation and histopathological features of the renal cell carcinoma are presented.

Entities:  

Mesh:

Year:  2011        PMID: 21751003     DOI: 10.1007/s10689-011-9467-5

Source DB:  PubMed          Journal:  Fam Cancer        ISSN: 1389-9600            Impact factor:   2.375


  19 in total

1.  Cancer risks in BRCA1 carriers: time for the next generation of studies.

Authors:  Stephen B Gruber; Gloria M Petersen
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

2.  BRCA1 2080insA mutation in familial breast cancer.

Authors:  Aliya S Alansari; Mansour Al-Moundhri; Marium M Al-Nabhani; Shoaib A Al-Zidjali
Journal:  Breast Cancer Res Treat       Date:  2008-03-14       Impact factor: 4.872

3.  Cancer risks in BRCA2 mutation carriers.

Authors: 
Journal:  J Natl Cancer Inst       Date:  1999-08-04       Impact factor: 13.506

4.  Risk of endometrial carcinoma associated with BRCA mutation.

Authors:  D A Levine; O Lin; R R Barakat; M E Robson; D McDermott; L Cohen; J Satagopan; K Offit; J Boyd
Journal:  Gynecol Oncol       Date:  2001-03       Impact factor: 5.482

5.  Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

Authors:  D Ford; D F Easton; M Stratton; S Narod; D Goldgar; P Devilee; D T Bishop; B Weber; G Lenoir; J Chang-Claude; H Sobol; M D Teare; J Struewing; A Arason; S Scherneck; J Peto; T R Rebbeck; P Tonin; S Neuhausen; R Barkardottir; J Eyfjord; H Lynch; B A Ponder; S A Gayther; M Zelada-Hedman
Journal:  Am J Hum Genet       Date:  1998-03       Impact factor: 11.025

6.  Cancer Incidence in BRCA1 mutation carriers.

Authors:  Deborah Thompson; Douglas F Easton
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

7.  Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program.

Authors:  Marcia S Brose; Timothy R Rebbeck; Kathleen A Calzone; Jill E Stopfer; Katherine L Nathanson; Barbara L Weber
Journal:  J Natl Cancer Inst       Date:  2002-09-18       Impact factor: 13.506

8.  BRCA germline mutations in Jewish women with uterine serous papillary carcinoma.

Authors:  Ofer Lavie; Gila Hornreich; Alon Ben-Arie; Gad Rennert; Yoram Cohen; Rehuven Keidar; Shlomi Sagi; Efrat Levy Lahad; Ron Auslander; Uzi Beller
Journal:  Gynecol Oncol       Date:  2004-02       Impact factor: 5.482

9.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

10.  Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan.

Authors:  Alexander Liede; Imtiaz A Malik; Zeba Aziz; Patricia de los Rios Pd; Elaine Kwan; Steven A Narod
Journal:  Am J Hum Genet       Date:  2002-08-13       Impact factor: 11.025

View more
  6 in total

1.  Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation.

Authors:  Anson Snow; Charite Ricker; Gino K In
Journal:  BMJ Case Rep       Date:  2019-06-20

2.  Outcome of genetic evaluation of patients with kidney cancer referred for suspected hereditary cancer syndromes.

Authors:  Kelly L Stratton; Shaheen Alanee; Emily A Glogowski; Kasmintan A Schrader; Rohini Rau-Murthy; Robert Klein; Paul Russo; Jonathan Coleman; Kenneth Offit
Journal:  Urol Oncol       Date:  2015-12-23       Impact factor: 3.498

3.  Germline mutations of renal cancer predisposition genes and clinical relevance in Chinese patients with sporadic, early-onset disease.

Authors:  Junlong Wu; Hongkai Wang; Christopher J Ricketts; Youfeng Yang; Maria J Merino; Hailiang Zhang; Guohai Shi; Hualei Gan; W Marston Linehan; Yao Zhu; Dingwei Ye
Journal:  Cancer       Date:  2018-12-12       Impact factor: 6.860

4.  Absence of loss of heterozygosity of BRCA1 in a renal tumor from a BRCA1 germline mutation carrier.

Authors:  Shaheen Alanee; Sohela Shah; Rajmohan Murali; Rohini Rau-Murthy; Kasmintan A Schrader; Kenneth Offit
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

5.  Hereditary and non-hereditary branches of family eligible for BRCA test: cancers in other sites.

Authors:  M Digennaro; D Sambiasi; S Tommasi; B Pilato; S Diotaiuti; A Kardhashi; G Trojano; A Tufaro; A V Paradiso
Journal:  Hered Cancer Clin Pract       Date:  2017-05-25       Impact factor: 2.857

6.  BRCA1 regulation on β-hCG: a mechanism for tumorigenicity in BRCA1 defective breast cancer.

Authors:  S K Sengodan; R Nadhan; R S Nair; S K Hemalatha; V Somasundaram; R R Sushama; A Rajan; N R Latha; G R Varghese; R K Thankappan; J M Kumar; A Chil; T V Anilkumar; P Srinivas
Journal:  Oncogenesis       Date:  2017-09-04       Impact factor: 7.485

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.